The Status of Biomarker Research in Low-Grade Gliomas

The FDA approved adjuvant alectinib following tumor resection for the treatment of patients with ALK-positive non-small cell lung cancer.

In season 4, episode 10 of Targeted Talks, Craig Horbinski, MD, PhD, reviews the clinical practice guidelines for central nervous system cancers.

Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.

Jeff Yorio, MD, discussed the unmet needs among patients with melanoma and plans for a phase 3 study assessing an mRNA vaccine.

In an interview with Targeted Oncology, Sara Kerr, MD discussed the evolution of genomic testing for patients with cancer and highlighted the program used at Allina Health.

In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.